Taysha Gene TherapiesTSHA
Recorded

Taysha Gene Therapies 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 2 minParticipants17

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Thank you for standing by, and welcome to Taysha Gene Therapies Third Quarter 2026 Financial Results Conference Call. Currently, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. To remove yourself from the queue, you may press star 11 again. I would now like to hand the call over to Stephanie Webster. Please go ahead. Thank you.

Stephanie WebsterSenior Manager of Corporate Communications

Good morning, and welcome to Taysha's Third Quarter 2026 Financial Results and Corporate Update Conference Call. Earlier today, Taysha issued a press release announcing financial results for the quarter ended September 30, 2026. A copy of this press release is available on the company's website and through our SEC filings. Joining me on today's call are Sean Nolan, Taysha's Chief Executive Officer, Suku Nagendran, President and Head of R&D, and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks.

Stephanie WebsterSenior Manager of Corporate Communications

On today's call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development, and regulatory plans for our product candidates, including the timing of initiating additional trials, reporting data from our clinical trials, and making regulatory submissions, timing or outcomes of communications with the FDA on the regulatory pathway for TSHA-102, the potential for the product candidate to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, our ability to realize the benefits of Breakthrough Therapy designation for TSHA-102, our ability to drive long-term value for stockholders, and the market opportunity for our program.

Stephanie WebsterSenior Manager of Corporate Communications

This call may also contain forward-looking statements relating to Taysha's growth, forecasted cash runway, and future operating results, discovery and development of product candidates, including our potential nomination of an additional gene therapy candidate in the first half of 2027, manufacturing and commercial readiness activities, strategic alliances, and intellectual property, as well as matters that are not historical facts or information. Various risks may cause Taysha's actual results to differ materially from those stated or implied in such forward-looking statements. For a list and description of the risks and uncertainties that we face, please see the reports we have filed with the SEC, including in our annual report on Form 10-K for the full year ended December 31, 2025, that we filed on March 19, 2026. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 12, 2026.

Stephanie WebsterSenior Manager of Corporate Communications

Taysha undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities laws. With that, I would now like to turn the call over to our CEO, Sean Nolan.

Sean NolanCEO

Thank you, Stephanie, and welcome everyone to our Third Quarter 2026 Financial Results and Corporate Update Conference Call. On today's call, I will begin with an update on our recent clinical, manufacturing, and commercial readiness activities. Suku Nagendran, President and Head of R&D, will then provide an update on the TSHA-102 program. Kamran Alam, our Chief Financial Officer, will follow up with a financial update. Finally, I will provide closing remarks before opening the call up to questions. During the Q&A, Fred Porter, Chief of Staff and Technical Operations Officer, will also be available for questions. The third quarter marked another period of strong execution for Taysha, during which we made meaningful progress across our clinical, manufacturing, and commercial readiness activities, supporting a potential BLA submission and the potential future commercialization of TSHA-102.

Sean NolanCEO

As we round out the year, we remain focused on building upon the robust dataset generated thus far in preparation for a potentially catalyst-rich period ahead, including top-line data from the REVEAL pivotal trial six-month interim analysis and potential FDA feedback on the BLA submission pathway expected in the first half of 2027. I'll first touch on our clinical progress, which Suku will elaborate on later on the call. Following the completion of dosing in both the REVEAL pivotal and ASPIRE trials, we are pleased to announce that all 33 patients dosed with TSHA-102, 29 in the REVEAL Phase I/II and pivotal trials, and four in the ASPIRE trial, have cleared the acute post-dosing safety monitoring period associated with AAV gene therapies. The last pivotal trial patient was dosed over four and a half months ago, and the last ASPIRE patient was dosed over three months ago.

Sean NolanCEO

We are very encouraged by our clearance of the acute safety window, which continues to demonstrate that TSHA-102 is well tolerated in all patients. This represents a key milestone for our program and gives us further confidence in the favorable safety profile observed to date and the continued advancement of TSHA-102 toward a potential BLA submission and potential future commercialization. As a reminder, once all patients in the REVEAL pivotal trial complete six months of follow-up, we will conduct an interim analysis, which may serve as the basis of our planned BLA submission and potentially accelerate our submission timeline by at least two full quarters relative to filing on the 12-month data. We continue to expect to report full top-line data from the interim analysis and potential feedback from the FDA on next steps in the BLA submission pathway in the first half of 2027.

Sean NolanCEO

Both high and low-dose TSHA-102 continue to be generally well tolerated. Notably, across the broader TSHA-102 clinical program, which began over three years ago, 33 patients spanning a broad range of ages, genotypes, and disease severities have been treated, with no severe treatment-related serious adverse events or dose-limiting toxicities reported as of the November 2026 data cutoff, supporting a favorable and consistent safety profile for trial participants across the program. I also want to touch on our commercial readiness efforts and the achievement of a major manufacturing milestone in the fourth quarter of 2026, with successful completion of our BLA-enabling process performance qualification, or PPQ, manufacturing campaign for TSHA-102.

Sean NolanCEO

Recall, following a Type C meeting in January 2026, we aligned with the FDA on our proposed PPQ strategy, including the production of commercial-scale drug product batches required to validate our final TSHA-102 commercial manufacturing process in support of our planned BLA submission. We have now completed the BLA-enabling PPQ manufacturing campaign for TSHA-102, with all process parameters and analytical results meeting the predefined product specifications, as well as comparability criteria for commercial product and clinical material. In addition, our assessment of comparability between PPQ commercial product and the clinical trial material conducted under the FDA-aligned strategy supports the potential inclusion of the REVEAL Part A data in the planned BLA submission, further supporting the potential for a BLA submission based on the pivotal six-month trial interim analysis.

Sean NolanCEO

We are also very pleased with the yield and the number of finished good doses manufactured from each of our PPQ batches, which we believe should translate to efficient and favorable cost of goods sold to support our potential commercial launch. Additionally, the commercial manufacturing process consistently achieved a single-digit empty capsid percentage, an important indicator of product quality that contributes to patient safety. These results demonstrate our ability to consistently manufacture high-quality product at the scale required to support the potential commercial demand and potential commercialization. We look forward to sharing these data and finalizing our CMC plan with FDA at a Type B meeting expected later in this fourth quarter.

Sean NolanCEO

Beyond manufacturing, we also continue to advance our broader commercial readiness efforts during the third quarter, further building out our commercial organization and advancing key market access initiatives, including expanding our payer team, conducting pre-approved information exchange discussions with payers, progressing site readiness activities at institutions, and advancing trade and distribution readiness activities to support the potential launch of TSHA-102. We believe the progress made across clinical manufacturing and commercial readiness efforts has positioned us well for multiple key upcoming regulatory interactions. In the fourth quarter, we plan to discuss the manufacturing data with the FDA to further strengthen the CMC package. Thereafter, we plan to engage with the FDA on next steps in a potential BLA submission pathway, and we will share the feedback from this meeting, along with the top-line data from the six-month interim pivotal trial analysis in the first half of 2027.

Sean NolanCEO

With multiple potential milestones on the horizon for Taysha's Rett program, we continue to leverage our expertise in CNS genetic medicines as we begin to position Taysha as a broader genetic medicines franchise. We expect to nominate an additional gene therapy development candidate targeting a CNS disorder with high unmet medical need and robust commercial opportunity and commence preclinical development activities in the first half of 2027. With that, I'll turn the call over to Suku.

Suku NagendranPresident and Head of R&D

Thank you. As Sean highlighted, we achieved several important milestones this quarter that we believe further strengthen the foundation of TSHA-102 and its path towards potential registration. As a reminder, 33 patients have been treated with TSHA-102 in the REVEAL Phase I/II, REVEAL pivotal, and ASPIRE trials. Across studies, dose levels, and broad patient population, TSHA-102 continues to be generally well tolerated, with no severe treatment-related serious adverse events or dose-limiting toxicities observed as of the November 2026 data cutoff. Notably, this favorable safety profile includes the ASPIRE trial, where no treatment-related serious adverse events have been reported amongst all participants as young as two and three years of age. As Sean mentioned, all patients in the REVEAL and ASPIRE trials have now cleared the acute post-dosing safety monitoring period commonly associated with AAV gene therapy.

Suku NagendranPresident and Head of R&D

With all patients in the REVEAL pivotal and ASPIRE trials now beyond this period, and no severe treatment-related serious adverse events or dose-limiting toxicities identified across all 33 patients. The growing safety dataset continues to support the favorable and consistent safety profile observed across our TSHA-102 program, and the benefit-risk profile continues to remain highly favorable. In the third quarter, we further highlighted the scientific foundation supporting TSHA-102 through multiple encore presentations at the 55th Child Neurology Society Annual Meeting. Taysha's oral presentation and three poster presentations featured data previously presented at the International Rett Syndrome Foundation Scientific Meeting, highlighting longer-term REVEAL Part A data, natural history analysis, and psychometric validation work, all of which support the clinical and regulatory foundation for TSHA-102.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day